TY - JOUR
T1 - Probiotics to young children with atopic dermatitis
T2 - a randomized placebo-controlled trial
AU - Gøbel, Rikke Juul
AU - Larsen, Nadejda Nikolajevna
AU - Mølgaard, Christian
AU - Jakobsen, Mogens
AU - Michaelsen, Kim F.
PY - 2010/5
Y1 - 2010/5
N2 - Impairment of the intestinal mucosal barrier is involved in the pathogenesis of atopic dermatitis (AD), and studies suggest that probiotics stabilize the intestinal barrier function and decrease gastrointestinal symptoms in children with AD. The purpose of this study was to evaluate the clinical and immunobgical changes of AD after consumption of the probiotic strains Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi-07. Double-blind randomized placebo-controlled intervention study. Fifty children (mean age 18 months) with AD received NCFM (1010 CFU/day), Bi-07 (1010 CFU/day) or placebo for 8 weeks. The immunological activity and clinical effect was evaluated by IgE, ECP, IL-10, IFN-γ, IL-31, faecal calprotectin and SCORAD index. There were no overall beneficial effects of the probiotic strains on the degree of AD measured by SCORAD index. However, a post hoc analysis showed a significant reduction in severity of AD in the Bi-07 group and together with the decreasing leveh of IFN-γ and IL-10 possible beneficial effects of this probiotic strain could be of interest. There was no effect on inflammatory markers or faecal calprotectin. The significant correlation between ECP and SCORAD index suggest the use of ECP as a measure of the degree of AD in children.
AB - Impairment of the intestinal mucosal barrier is involved in the pathogenesis of atopic dermatitis (AD), and studies suggest that probiotics stabilize the intestinal barrier function and decrease gastrointestinal symptoms in children with AD. The purpose of this study was to evaluate the clinical and immunobgical changes of AD after consumption of the probiotic strains Lactobacillus acidophilus NCFM and Bifidobacterium animalis subsp. lactis Bi-07. Double-blind randomized placebo-controlled intervention study. Fifty children (mean age 18 months) with AD received NCFM (1010 CFU/day), Bi-07 (1010 CFU/day) or placebo for 8 weeks. The immunological activity and clinical effect was evaluated by IgE, ECP, IL-10, IFN-γ, IL-31, faecal calprotectin and SCORAD index. There were no overall beneficial effects of the probiotic strains on the degree of AD measured by SCORAD index. However, a post hoc analysis showed a significant reduction in severity of AD in the Bi-07 group and together with the decreasing leveh of IFN-γ and IL-10 possible beneficial effects of this probiotic strain could be of interest. There was no effect on inflammatory markers or faecal calprotectin. The significant correlation between ECP and SCORAD index suggest the use of ECP as a measure of the degree of AD in children.
M3 - Journal article
SN - 1555-1431
VL - 5
SP - 53
EP - 60
JO - International Journal of Probiotics & Prebiotics
JF - International Journal of Probiotics & Prebiotics
IS - 2
ER -